Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study)-Reference-Cited by-同舟云学术

Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study)

Published:2024-04-24 Issue:6 Volume:15 Page:1403-1416
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Fukuda Masahiro^ORCID,Sakuma Ichiro,Wakasa Yutaka,Funayama Hideaki,Kondo Akira,Itabashi Naoki,Maruyama Yasuyuki,Kamiyama Takashi,Utsunomiya Yasunori,Yamauchi Akira,Yoshii Hidenori,Yamada Hirokazu,Mochizuki Koichi,Sugawara Masahiro,

Funder

Taisho Pharmaceutical Co., Ltd.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13300-024-01575-w.pdf

Reference22 articles.

1. Japan Diabetes Society. Japanese clinical practice guideline for diabetes 2022-2023. Bunkodo 2023.

2. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753–86.

3. Ishii H, Oda E. Reproducibility and validity of a satisfaction questionnaire on hypoglycemic agents: the Oral Hypoglycemic Agent Questionnaire (OHA-Q). Diabetol Int. 2012;3:152–63.

4. Nakajima H, Okada S, Mohri T, et al. Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study). Diabetol Metab Syndr. 2018;10:11.

5. Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14:505–24.